PARIS--(BUSINESS WIRE)--Regulatory News: ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of ...
During the R&D Day event, ALX Oncology leadership will discuss the mechanistic rationale and clinical data that support further development of evorpacept with anti-cancer antibodies. In addition to ...
SAN DIEGO, June 8, 2026 /PRNewswire/ -- Sapu Bioscience LLC announced the expansion of its Phase 1b clinical development program for Sapu003 (Everolimus for Injection) and the appointment of Global ...
Pfizer is continuing to advance the first full agonist oral GLP-1-RA candidate danuglipron toward late-state development Danuglipron is the largest oral, small molecule GLP-1-RA clinical development ...
WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer announced it is further investing in MOONRAKER— its clinical development program to investigate Kerendia ® (finerenone) as a potential treatment for heart ...
The US Food and Drug Administration (FDA) is seeking comments on a pilot program where qualified external institutions will ...
Why does it take a new drug 10 years, on average, to come to market? Part of the reason lies in the dead time in the process. Historically, trials have required tedious tabulations and repeated ...
Recent Clinical Progress, Enrollment Achievements, Expanded Intellectual Property Portfolio and Strengthened Financial Position Support a Potentially Transformative 12-Month Value Creation Opportunity ...
How do you approach clinical trial design for cell and gene therapies? There are a lot of similarities, but also some notable differences that I have encountered the last 15 years working in multiple ...
– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial – Exelixis, Inc. (Nasdaq: EXEL) today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results